Trial
NCT03580044
Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Pfizer
Collaborators
Allergan
Condition
Serious Bacterial Infection
Intervention
ATM-AVI
Why stopped
Recruitment of patients with serious infections caused by gram-negative bacteria producing MBL has been challenging. Date study terminated: 16-Dec-2022.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-02-02